Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 17, 1999
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group
E Kucera, P Speiser, M Gnant, et al.
British Journal of Cancer
|
April 18, 2013
Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma
A Aigelsreiter, A L Ress, K Bettermann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor
H Stöger, H Samonigg, M Krainer, et al.
British Journal of Cancer
|
July 23, 2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
M Gnant, G Pfeiler, H Stöger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
R Jakesz, H Hausmaninger, K Haider, et al.
Onkologie
|
May 29, 2003
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients
F Ploner, R Jakesz, H Hausmaninger, et al.
The Pharmacogenomics Journal
|
February 11, 2015
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy
J Szkandera, S Herzog, M Pichler, et al.
British Journal of Cancer
|
November 9, 2013
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients
J Szkandera, M Stotz, G Absenger, et al.
British Journal of Cancer
|
September 27, 2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
W Schippinger, H Samonigg, R Schaberl-Moser, et al.
British Journal of Cancer
|
June 27, 2013
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
M Stotz, A Gerger, F Eisner, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
European Journal of Cancer (Oxford, England : 1990)
|
August 17, 1999
Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group
E Kucera, P Speiser, M Gnant, et al.
British Journal of Cancer
|
April 18, 2013
Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma
A Aigelsreiter, A L Ress, K Bettermann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 26, 1998
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor
H Stöger, H Samonigg, M Krainer, et al.
British Journal of Cancer
|
July 23, 2013
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial
M Gnant, G Pfeiler, H Stöger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
R Jakesz, H Hausmaninger, K Haider, et al.
Onkologie
|
May 29, 2003
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients
F Ploner, R Jakesz, H Hausmaninger, et al.
The Pharmacogenomics Journal
|
February 11, 2015
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy
J Szkandera, S Herzog, M Pichler, et al.
British Journal of Cancer
|
November 9, 2013
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients
J Szkandera, M Stotz, G Absenger, et al.
British Journal of Cancer
|
September 27, 2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
W Schippinger, H Samonigg, R Schaberl-Moser, et al.
British Journal of Cancer
|
June 27, 2013
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
M Stotz, A Gerger, F Eisner, et al.
Page
of 8